Levbid review

Levbid, which is generically prescribed as L-hyoscyamine, is commonly used to treat colitis, spastic bladder, infant colic, diverticulitis, renal and biliary colic, irritable bowel syndrome, peptic ulcer, pancreatitis, splenic flexure syndrome, and excessive drooling and sweating associated with diseases such as Parkinson’s disease, or additional diseases that contribute to difficulty in controlling bodily secretions.

Levbid is not appropriate for everyone. A thorough medical history should be assessed prior to prescribing this medication. Patients with a medical history which includes glaucoma, kidney disease, blockage of the urinary tract, difficulty urinating, blockage of the bowels, severe ulcerative colitis or ulcerative colitis that is complicated by toxic magecolon, myasthenia gravis, liver disease, thyroid problems, ulcerative colitis, numbness or tingling in the hands or feet, high blood pressure, heart disease, hiatal hernia, reflux disease, enlarged prostate, asthma, chronic lung disease, or allergies may not be able to take Levbid or may require careful monitoring while undergoing drug therapy with this medication, depending on the condition and the severity of the condition.

The American Food and Drug Administration rated Levbid as a pregnancy risk category C. It has yet to be determined whether or not Levbid will cause harm or birth defects to an unborn baby. It has yet to be determined whether or not this medication passes into the mother’s breast milk and affects a nursing baby. The prescribing physician should avoid prescribing Levbid to women who are pregnant, nursing, or have a high likelihood of becoming pregnant.

There is a risk of side effects associated with Levbid, some of which are severe. A patient who is experiencing a serious side effect or an allergic reaction should seek immediate emergency medical attention. An allergic reaction will present with side effects such as facial swelling, including swelling of the lips, mouth, throat, or tongue, hives, and difficulty breathing. Other serious side effects which require immediate emergency medical attention include symptoms such as skin rash or flushing, eye pain, fast heart rate, or irregular heart rate. Less serious side effects typically do not require emergency medical attention but should be reported to the prescribing physician. Patients should be encouraged to report all side effects. Less serious side effects include symptoms such as weakness, nervousness, changes in taste, bloating, headache dizziness, lightheadedness, blurry vision, enlarged pupils, sensitivity to light, nausea, heartburn, constipation, difficulty urinating, decreased ability to sweat, nasal congestion, stuffiness, or dry mouth.. Less serious side effects can often be reduced to a tolerable level by reducing the dosage of Levbid.

Levbid should be taken exactly as it has been prescribed by the physician. If the patient misses a dose, the dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid the potential for an overdose. The patient should never take a double dose of this medication. If an overdose is suspected, the patient should seek immediate emergency medical attention. An overdose will present with symptoms such as anxiety, weak pulse, blurry vision, dilated pupils, hot or dry skin, dizziness, drowsiness, confusion, irregular heart rate and seizures.

There is a potential risk of negative drug interactions associated with Levbid. A thorough medical history should be understood prior to prescribing this medication. Patients should be urged to inquire with the prescribing physician before taking any new medications, including over the counter medications and herbal remedies. Medications with a known negative drug interactions with Levbid include amantadine, quinidine, antihistamines, decongestants, appetite suppressants, phenothiazines, and tricyclic antidepressants.

Levbid has the following structural formula:

Chemical structure of levbid

• Molecular formula of levbid is C17H23NO3
• Chemical IUPAC Name is (8-methyl-8-azabicyclo[3.2.1]oct-3-yl)3-hydroxy-2-phenyl-propanoate
• Molecular weight is 289.369 g/mol
Levbid available : 0.375mg tablets

Generic name: Hyoscyamine

Brand name(s): Anaspaz, Cystospaz, Daturine, Duboisine, Duretter, Egacene, Egazil, Gastrosed, Hyocyamine, Levsin, Levsinex, Peptard

  Your Levbid review